Evidence to Consider when Advising Patients on Buprenorphine Treatment Duration for Opioid Use Disorder

1.5 CME/CE available!

Presenters: Ingrid A. Binswanger, MD, MPH, MS and Jason M. Glanz, PhD, MS, both from Institute for Health Research (Kaiser Permanente). More about the speakers

Retention on buprenorphine for opioid use disorder is known to be poor across health systems, despite established mortality benefits of treatment, and little is known about how to counsel patients who want to stop using buprenorphine or who have to stop due to barriers to ongoing care.

This webinar will consider what the evidence from a prescription opioid registry developed by NIDA Clinical Trials Network study CTN-0084 suggests for individuals who discontinue buprenorphine, including whether there was a length-of-treatment exposure associated with improved outcomes. Implications for patient education and shared decision-making will be considered. Understanding the optimal length of treatment after which individuals can safely discontinue buprenorphine could help patients better understand what treatment might look like at the outset, supporting informed decision-making and potentially improving both treatment retention and outcomes.